PET/MR in invasive ductal breast cancer

correlation between imaging markers and histological phenotype

Onofrio Antonio Catalano, Gary Lloyd Horn, Alberto Signore, Carlo Iannace, Maria Lepore, Mark Vangel, Angelo Luongo, Marco Catalano, Constance Lehman, Marco Salvatore, Andrea Soricelli, Ciprian Catana, Umar Mahmood, Bruce Robert Rosen

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background:Differences in genetics and receptor expression (phenotypes) of invasive ductal breast cancer (IDC) impact on prognosis and treatment response. Immunohistochemistry (IHC), the most used technique for IDC phenotyping, has some limitations including its invasiveness. We explored the possibility of contrast-enhanced positron emission tomography magnetic resonance (CE-FDG PET/MR) to discriminate IDC phenotypes.Methods:21 IDC patients with IHC assessment of oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor-2 (HER2), and antigen Ki-67 (Ki67) underwent CE-FDG PET/MR. Magnetic resonance-perfusion biomarkers, apparent diffusion coefficient (ADC), and standard uptake value (SUV) were compared with IHC markers and phenotypes, using a Student’s t-test and one-way ANOVA.Results:ER/PR− tumours demonstrated higher Kepmean and SUVmax than ER or PR+ tumours. HER2− tumours displayed higher ADCmean, Kepmean, and SUVmax than HER2+tumours. Only ADCmean discriminated Ki67⩽14% tumours (lower ADCmean) from Ki67>14% tumours. PET/MR biomarkers correlated with IHC phenotype in 13 out of 21 patients (62%; P=0.001).Conclusions:Positron emission tomography magnetic resonance might non-invasively help discriminate IDC phenotypes, helping to optimise individual therapy options.British Journal of Cancer advance online publication, 16 February 2017; doi:10.1038/bjc.2017.26 www.bjcancer.com.

Original languageEnglish (US)
JournalBritish Journal of Cancer
DOIs
StateAccepted/In press - Feb 16 2017

Fingerprint

Breast Neoplasms
Phenotype
Progesterone Receptors
Immunohistochemistry
Neoplasms
Epidermal Growth Factor
Magnetic Resonance Spectroscopy
Positron-Emission Tomography
Biomarkers
Ki-67 Antigen
Estrogen Receptors
Publications
Analysis of Variance
Perfusion
Students
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Catalano, O. A., Horn, G. L., Signore, A., Iannace, C., Lepore, M., Vangel, M., ... Rosen, B. R. (Accepted/In press). PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype. British Journal of Cancer. https://doi.org/10.1038/bjc.2017.26

PET/MR in invasive ductal breast cancer : correlation between imaging markers and histological phenotype. / Catalano, Onofrio Antonio; Horn, Gary Lloyd; Signore, Alberto; Iannace, Carlo; Lepore, Maria; Vangel, Mark; Luongo, Angelo; Catalano, Marco; Lehman, Constance; Salvatore, Marco; Soricelli, Andrea; Catana, Ciprian; Mahmood, Umar; Rosen, Bruce Robert.

In: British Journal of Cancer, 16.02.2017.

Research output: Contribution to journalArticle

Catalano, OA, Horn, GL, Signore, A, Iannace, C, Lepore, M, Vangel, M, Luongo, A, Catalano, M, Lehman, C, Salvatore, M, Soricelli, A, Catana, C, Mahmood, U & Rosen, BR 2017, 'PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype', British Journal of Cancer. https://doi.org/10.1038/bjc.2017.26
Catalano, Onofrio Antonio ; Horn, Gary Lloyd ; Signore, Alberto ; Iannace, Carlo ; Lepore, Maria ; Vangel, Mark ; Luongo, Angelo ; Catalano, Marco ; Lehman, Constance ; Salvatore, Marco ; Soricelli, Andrea ; Catana, Ciprian ; Mahmood, Umar ; Rosen, Bruce Robert. / PET/MR in invasive ductal breast cancer : correlation between imaging markers and histological phenotype. In: British Journal of Cancer. 2017.
@article{9a9517b83109475da66e5170f8fa63b6,
title = "PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype",
abstract = "Background:Differences in genetics and receptor expression (phenotypes) of invasive ductal breast cancer (IDC) impact on prognosis and treatment response. Immunohistochemistry (IHC), the most used technique for IDC phenotyping, has some limitations including its invasiveness. We explored the possibility of contrast-enhanced positron emission tomography magnetic resonance (CE-FDG PET/MR) to discriminate IDC phenotypes.Methods:21 IDC patients with IHC assessment of oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor-2 (HER2), and antigen Ki-67 (Ki67) underwent CE-FDG PET/MR. Magnetic resonance-perfusion biomarkers, apparent diffusion coefficient (ADC), and standard uptake value (SUV) were compared with IHC markers and phenotypes, using a Student’s t-test and one-way ANOVA.Results:ER/PR− tumours demonstrated higher Kepmean and SUVmax than ER or PR+ tumours. HER2− tumours displayed higher ADCmean, Kepmean, and SUVmax than HER2+tumours. Only ADCmean discriminated Ki67⩽14{\%} tumours (lower ADCmean) from Ki67>14{\%} tumours. PET/MR biomarkers correlated with IHC phenotype in 13 out of 21 patients (62{\%}; P=0.001).Conclusions:Positron emission tomography magnetic resonance might non-invasively help discriminate IDC phenotypes, helping to optimise individual therapy options.British Journal of Cancer advance online publication, 16 February 2017; doi:10.1038/bjc.2017.26 www.bjcancer.com.",
author = "Catalano, {Onofrio Antonio} and Horn, {Gary Lloyd} and Alberto Signore and Carlo Iannace and Maria Lepore and Mark Vangel and Angelo Luongo and Marco Catalano and Constance Lehman and Marco Salvatore and Andrea Soricelli and Ciprian Catana and Umar Mahmood and Rosen, {Bruce Robert}",
year = "2017",
month = "2",
day = "16",
doi = "10.1038/bjc.2017.26",
language = "English (US)",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - PET/MR in invasive ductal breast cancer

T2 - correlation between imaging markers and histological phenotype

AU - Catalano, Onofrio Antonio

AU - Horn, Gary Lloyd

AU - Signore, Alberto

AU - Iannace, Carlo

AU - Lepore, Maria

AU - Vangel, Mark

AU - Luongo, Angelo

AU - Catalano, Marco

AU - Lehman, Constance

AU - Salvatore, Marco

AU - Soricelli, Andrea

AU - Catana, Ciprian

AU - Mahmood, Umar

AU - Rosen, Bruce Robert

PY - 2017/2/16

Y1 - 2017/2/16

N2 - Background:Differences in genetics and receptor expression (phenotypes) of invasive ductal breast cancer (IDC) impact on prognosis and treatment response. Immunohistochemistry (IHC), the most used technique for IDC phenotyping, has some limitations including its invasiveness. We explored the possibility of contrast-enhanced positron emission tomography magnetic resonance (CE-FDG PET/MR) to discriminate IDC phenotypes.Methods:21 IDC patients with IHC assessment of oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor-2 (HER2), and antigen Ki-67 (Ki67) underwent CE-FDG PET/MR. Magnetic resonance-perfusion biomarkers, apparent diffusion coefficient (ADC), and standard uptake value (SUV) were compared with IHC markers and phenotypes, using a Student’s t-test and one-way ANOVA.Results:ER/PR− tumours demonstrated higher Kepmean and SUVmax than ER or PR+ tumours. HER2− tumours displayed higher ADCmean, Kepmean, and SUVmax than HER2+tumours. Only ADCmean discriminated Ki67⩽14% tumours (lower ADCmean) from Ki67>14% tumours. PET/MR biomarkers correlated with IHC phenotype in 13 out of 21 patients (62%; P=0.001).Conclusions:Positron emission tomography magnetic resonance might non-invasively help discriminate IDC phenotypes, helping to optimise individual therapy options.British Journal of Cancer advance online publication, 16 February 2017; doi:10.1038/bjc.2017.26 www.bjcancer.com.

AB - Background:Differences in genetics and receptor expression (phenotypes) of invasive ductal breast cancer (IDC) impact on prognosis and treatment response. Immunohistochemistry (IHC), the most used technique for IDC phenotyping, has some limitations including its invasiveness. We explored the possibility of contrast-enhanced positron emission tomography magnetic resonance (CE-FDG PET/MR) to discriminate IDC phenotypes.Methods:21 IDC patients with IHC assessment of oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor-2 (HER2), and antigen Ki-67 (Ki67) underwent CE-FDG PET/MR. Magnetic resonance-perfusion biomarkers, apparent diffusion coefficient (ADC), and standard uptake value (SUV) were compared with IHC markers and phenotypes, using a Student’s t-test and one-way ANOVA.Results:ER/PR− tumours demonstrated higher Kepmean and SUVmax than ER or PR+ tumours. HER2− tumours displayed higher ADCmean, Kepmean, and SUVmax than HER2+tumours. Only ADCmean discriminated Ki67⩽14% tumours (lower ADCmean) from Ki67>14% tumours. PET/MR biomarkers correlated with IHC phenotype in 13 out of 21 patients (62%; P=0.001).Conclusions:Positron emission tomography magnetic resonance might non-invasively help discriminate IDC phenotypes, helping to optimise individual therapy options.British Journal of Cancer advance online publication, 16 February 2017; doi:10.1038/bjc.2017.26 www.bjcancer.com.

UR - http://www.scopus.com/inward/record.url?scp=85013073372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013073372&partnerID=8YFLogxK

U2 - 10.1038/bjc.2017.26

DO - 10.1038/bjc.2017.26

M3 - Article

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

ER -